Sign in
NAMS Stock Price, Chart, Stats & News
NewAmsterdam Pharma Company N.V.
Save
3.79B
Market cap
–
Current P/E
–
Forward P/E
NAMS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.74% |
Operating margin | -1002.90% |
Pretax margin | -905.74% |
Net margin | -905.74% |
Effective tax rate | – |
ROA | -26.49% |
ROE | -27.47% |
D/E | 0.00x |
Interest coverage ratio | – |
NAMS valuation
P/E | – |
P/S | 153.18x |
P/B | 5.02x |
P/CF | -23.21x |
P/FCF | -23.29x |
P/OCF | -23.21x |
PEG | -1.06x |
EV multiple | -16.25x |
About
NewAmsterdam Pharma Company N. V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Similar securities
Based on sector and market capitalization
Report issue